Thromboxane A2 promotes interleukin-6 biosynthesis mediated by an activation of cyclic AMP-response element-binding protein in 1321N1 human astrocytoma cells

Yutaro Obara, Hitoshi Kurose, Norimichi Nakahata

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

1321N1 human astrocytoma cells express thromboxane A2 (TXA 2) receptors (TP). However, physiological consequences of TXA 2 signaling in glial cells remain unclear. Herein, we show that TXA2 promotes interleukin-6 (IL-6) biosynthesis in glial cells. A TP agonist, 9,11-dideoxy-9α,11α-methanoepoxyprosta-5Z,13E-dien-1-oic acid (U46619), enhanced IL-6 production in both 1321N1 cells and cultured mouse astrocytes. It has been shown that IL-6 gene expression is regulated by various transcription factors. Among them, we found a significant increase in cyclic AMP-response element-binding protein (CREB) activity with its phosphorylation at Ser133 by U46619 in 1321N1 cells. Although U46619 increased IL-6 promoter activity, a mutation at cyclic AMP-response element (CRE) on the promoter clearly suppressed the effect, suggesting that CRE is involved in U46619-induced IL-6 expression. Furthermore, both CREB and IL-6 promoter activities were suppressed by SB203580 [4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4- pyridyl)-1H-imidazole], a p38 mitogen-activated protein kinase (MAPK) inhibitor, and H89 [N-[2-(4-bromocinnamylamino)-ethyl]-5-isoquinoline], a protein kinase A (PKA) inhibitor, indicating involvements of p38 MAPK and PKA in CREB activation and IL-6 expression. To determine which G-proteins are implicated in the U46619-induced IL-6 synthesis, the interfering mutants of Gαq, Gα12, or Gα13 were overexpressed in 1321N1 cells by adenoviral approach. It is noteworthy that the Gαq or Gα13 mutant blocked the IL-6 production by U46619. The constitutively active mutant of Gαq, Gα12, or Gα13 enhanced IL-6 production, indicating that Gαq and Gα13 were involved in U46619-induced IL-6 production. In conclusion, TXA2 enhances the IL-6 biosynthesis via the PKA p38 MAPK/CREB pathway in 1321N1 cells. IL-6 induction depends on Gαq and Gα13 as well. This is the first report showing TP-mediated IL-6 production in glial cells.

Original languageEnglish
Pages (from-to)670-679
Number of pages10
JournalMolecular Pharmacology
Volume68
Issue number3
DOIs
Publication statusPublished - Sep 1 2005

Fingerprint

Cyclic AMP Response Element-Binding Protein
Thromboxane A2
Astrocytoma
Interleukin-6
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
p38 Mitogen-Activated Protein Kinases
Cyclic AMP-Dependent Protein Kinases
Neuroglia
Response Elements
Protein Kinase Inhibitors
Cyclic AMP
Prostaglandin H2 Receptors Thromboxane A2
Mitogen-Activated Protein Kinase Kinases
GTP-Binding Proteins
Astrocytes

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmacology

Cite this

Thromboxane A2 promotes interleukin-6 biosynthesis mediated by an activation of cyclic AMP-response element-binding protein in 1321N1 human astrocytoma cells. / Obara, Yutaro; Kurose, Hitoshi; Nakahata, Norimichi.

In: Molecular Pharmacology, Vol. 68, No. 3, 01.09.2005, p. 670-679.

Research output: Contribution to journalArticle

@article{2d9f986239ed4a7f97ca7a373103d2d2,
title = "Thromboxane A2 promotes interleukin-6 biosynthesis mediated by an activation of cyclic AMP-response element-binding protein in 1321N1 human astrocytoma cells",
abstract = "1321N1 human astrocytoma cells express thromboxane A2 (TXA 2) receptors (TP). However, physiological consequences of TXA 2 signaling in glial cells remain unclear. Herein, we show that TXA2 promotes interleukin-6 (IL-6) biosynthesis in glial cells. A TP agonist, 9,11-dideoxy-9α,11α-methanoepoxyprosta-5Z,13E-dien-1-oic acid (U46619), enhanced IL-6 production in both 1321N1 cells and cultured mouse astrocytes. It has been shown that IL-6 gene expression is regulated by various transcription factors. Among them, we found a significant increase in cyclic AMP-response element-binding protein (CREB) activity with its phosphorylation at Ser133 by U46619 in 1321N1 cells. Although U46619 increased IL-6 promoter activity, a mutation at cyclic AMP-response element (CRE) on the promoter clearly suppressed the effect, suggesting that CRE is involved in U46619-induced IL-6 expression. Furthermore, both CREB and IL-6 promoter activities were suppressed by SB203580 [4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4- pyridyl)-1H-imidazole], a p38 mitogen-activated protein kinase (MAPK) inhibitor, and H89 [N-[2-(4-bromocinnamylamino)-ethyl]-5-isoquinoline], a protein kinase A (PKA) inhibitor, indicating involvements of p38 MAPK and PKA in CREB activation and IL-6 expression. To determine which G-proteins are implicated in the U46619-induced IL-6 synthesis, the interfering mutants of Gαq, Gα12, or Gα13 were overexpressed in 1321N1 cells by adenoviral approach. It is noteworthy that the Gαq or Gα13 mutant blocked the IL-6 production by U46619. The constitutively active mutant of Gαq, Gα12, or Gα13 enhanced IL-6 production, indicating that Gαq and Gα13 were involved in U46619-induced IL-6 production. In conclusion, TXA2 enhances the IL-6 biosynthesis via the PKA p38 MAPK/CREB pathway in 1321N1 cells. IL-6 induction depends on Gαq and Gα13 as well. This is the first report showing TP-mediated IL-6 production in glial cells.",
author = "Yutaro Obara and Hitoshi Kurose and Norimichi Nakahata",
year = "2005",
month = "9",
day = "1",
doi = "10.1124/mol.105.012922",
language = "English",
volume = "68",
pages = "670--679",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - Thromboxane A2 promotes interleukin-6 biosynthesis mediated by an activation of cyclic AMP-response element-binding protein in 1321N1 human astrocytoma cells

AU - Obara, Yutaro

AU - Kurose, Hitoshi

AU - Nakahata, Norimichi

PY - 2005/9/1

Y1 - 2005/9/1

N2 - 1321N1 human astrocytoma cells express thromboxane A2 (TXA 2) receptors (TP). However, physiological consequences of TXA 2 signaling in glial cells remain unclear. Herein, we show that TXA2 promotes interleukin-6 (IL-6) biosynthesis in glial cells. A TP agonist, 9,11-dideoxy-9α,11α-methanoepoxyprosta-5Z,13E-dien-1-oic acid (U46619), enhanced IL-6 production in both 1321N1 cells and cultured mouse astrocytes. It has been shown that IL-6 gene expression is regulated by various transcription factors. Among them, we found a significant increase in cyclic AMP-response element-binding protein (CREB) activity with its phosphorylation at Ser133 by U46619 in 1321N1 cells. Although U46619 increased IL-6 promoter activity, a mutation at cyclic AMP-response element (CRE) on the promoter clearly suppressed the effect, suggesting that CRE is involved in U46619-induced IL-6 expression. Furthermore, both CREB and IL-6 promoter activities were suppressed by SB203580 [4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4- pyridyl)-1H-imidazole], a p38 mitogen-activated protein kinase (MAPK) inhibitor, and H89 [N-[2-(4-bromocinnamylamino)-ethyl]-5-isoquinoline], a protein kinase A (PKA) inhibitor, indicating involvements of p38 MAPK and PKA in CREB activation and IL-6 expression. To determine which G-proteins are implicated in the U46619-induced IL-6 synthesis, the interfering mutants of Gαq, Gα12, or Gα13 were overexpressed in 1321N1 cells by adenoviral approach. It is noteworthy that the Gαq or Gα13 mutant blocked the IL-6 production by U46619. The constitutively active mutant of Gαq, Gα12, or Gα13 enhanced IL-6 production, indicating that Gαq and Gα13 were involved in U46619-induced IL-6 production. In conclusion, TXA2 enhances the IL-6 biosynthesis via the PKA p38 MAPK/CREB pathway in 1321N1 cells. IL-6 induction depends on Gαq and Gα13 as well. This is the first report showing TP-mediated IL-6 production in glial cells.

AB - 1321N1 human astrocytoma cells express thromboxane A2 (TXA 2) receptors (TP). However, physiological consequences of TXA 2 signaling in glial cells remain unclear. Herein, we show that TXA2 promotes interleukin-6 (IL-6) biosynthesis in glial cells. A TP agonist, 9,11-dideoxy-9α,11α-methanoepoxyprosta-5Z,13E-dien-1-oic acid (U46619), enhanced IL-6 production in both 1321N1 cells and cultured mouse astrocytes. It has been shown that IL-6 gene expression is regulated by various transcription factors. Among them, we found a significant increase in cyclic AMP-response element-binding protein (CREB) activity with its phosphorylation at Ser133 by U46619 in 1321N1 cells. Although U46619 increased IL-6 promoter activity, a mutation at cyclic AMP-response element (CRE) on the promoter clearly suppressed the effect, suggesting that CRE is involved in U46619-induced IL-6 expression. Furthermore, both CREB and IL-6 promoter activities were suppressed by SB203580 [4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4- pyridyl)-1H-imidazole], a p38 mitogen-activated protein kinase (MAPK) inhibitor, and H89 [N-[2-(4-bromocinnamylamino)-ethyl]-5-isoquinoline], a protein kinase A (PKA) inhibitor, indicating involvements of p38 MAPK and PKA in CREB activation and IL-6 expression. To determine which G-proteins are implicated in the U46619-induced IL-6 synthesis, the interfering mutants of Gαq, Gα12, or Gα13 were overexpressed in 1321N1 cells by adenoviral approach. It is noteworthy that the Gαq or Gα13 mutant blocked the IL-6 production by U46619. The constitutively active mutant of Gαq, Gα12, or Gα13 enhanced IL-6 production, indicating that Gαq and Gα13 were involved in U46619-induced IL-6 production. In conclusion, TXA2 enhances the IL-6 biosynthesis via the PKA p38 MAPK/CREB pathway in 1321N1 cells. IL-6 induction depends on Gαq and Gα13 as well. This is the first report showing TP-mediated IL-6 production in glial cells.

UR - http://www.scopus.com/inward/record.url?scp=23944461833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23944461833&partnerID=8YFLogxK

U2 - 10.1124/mol.105.012922

DO - 10.1124/mol.105.012922

M3 - Article

C2 - 15967875

AN - SCOPUS:23944461833

VL - 68

SP - 670

EP - 679

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 3

ER -